Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other financing activities (2017 - 2025)

Sutro Biopharma's Other financing activities history spans 9 years, with the latest figure at $25000.0 for Q3 2025.

  • For Q3 2025, Other financing activities fell 66.22% year-over-year to $25000.0; the TTM value through Sep 2025 reached $290000.0, up 100.21%, while the annual FY2024 figure was $509000.0, 3.88% up from the prior year.
  • Other financing activities for Q3 2025 was $25000.0 at Sutro Biopharma, down from $61000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $580000.0 in Q3 2021 and bottomed at -$135.7 million in Q4 2023.
  • The 5-year median for Other financing activities is $55500.0 (2022), against an average of -$7.6 million.
  • The largest annual shift saw Other financing activities plummeted 7172.0% in 2023 before it soared 516.67% in 2024.
  • A 5-year view of Other financing activities shows it stood at -$84000.0 in 2021, then skyrocketed by 159.52% to $50000.0 in 2022, then plummeted by 271536.0% to -$135.7 million in 2023, then skyrocketed by 100.02% to $24000.0 in 2024, then increased by 4.17% to $25000.0 in 2025.
  • Per Business Quant, the three most recent readings for STRO's Other financing activities are $25000.0 (Q3 2025), $61000.0 (Q2 2025), and $180000.0 (Q1 2025).